

ASX ANNOUNCEMENT

20 July 2023

CLEANSING NOTICE**Notice under section 708A of the Corporations Act 2001 (Cth) (Act)**

In relation to the 36,857,143 Shares issued pursuant to the Placement, HeraMED hereby notifies ASX that:

1. the Company issued the Shares without disclosure to investors under Part 6D.2 of the Act;
2. this notice is given by HeraMED under paragraph 708A(5)(e) of the Act;
3. as at the date of this notice, HeraMED has complied with the provisions of chapter 2M of the Act as they apply to HeraMED and section 674 of the Act; and
4. as at the date of this notice, there is no information that is 'excluded information' under section 708A(7) and (8) of the Act.

This announcement has been authorised by the Board of HeraMED Limited.

-ENDS-

This announcement has been authorised by the Board of HeraMED Limited.

HeraMED Limited
Executive Chairman
Dr Ron Weinberger
E: ron@hera-med.com

Company Secretary
Jonathan Hart
E: Jonathan@hera-med.com

Investor Relations
Tim Chapman
T: +61 419 897 062
E: tchapman@claritycap.com.au

About HeraMED Limited (ASX:HMD):

HeraMED is an innovative medical data and technology company leading the digital transformation of maternity care by revolutionising the prenatal and postpartum experience with its hybrid maternity care platform. HeraMED offers a proprietary platform that utilises hardware and software to reshape the Doctor/Patient relationship using its clinically validated in-home foetal and maternal heart rate monitor, HeraBEAT, cloud computing, artificial intelligence, and big data.

About HeraCARE:

The Company's proprietary offering, HeraCARE, has been engineered to offer a fully integrated maternal health ecosystem designed to deliver better care at a lower cost, ensure expectant mothers are engaged, informed and well-supported, allow healthcare professionals to provide the highest quality care and enable early detection and prevention of potential risks.